First Off: Johnson & Johnson Submits Application to EMA for Oral Icotrokinra in Psoriasis
Johnson & Johnson has submitted an application to the European Medicines Agency (EMA) for what could be the first-ever approval of icotrokinra, a first-in-class investigational targeted oral peptide for the treatment of moderate-to-severe plaque psoriasis in people aged 12 and up, the Company reports.